Cardiomyopathy Medication Market Size, Revenue Analysis, Opportunities, Trends, Forecast Till 2030
The Global Cardiomyopathy Medication Market is anticipated to reach USD 620 Million by 2025 at a CAGR of ~4.60% during the forecast period.
Cardiomyopathy
is a disease that causes the thickening and enlargement of the heart muscles
and abnormal blood flow. Patients suffering from cardiomyopathy showcase
symptoms such as dizziness, coughing, fatigue, and swelling of the legs,
ankles, and feet.
Certain
factors that propel the growth of the global cardiomyopathy medication market
are the high patient pool of heart disease, focus on manufacturing medication
for cardiomyopathy treatment, and rising healthcare expenditure.
Request
Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8256
Currently,
the global cardiomyopathy medication market is dominated by several players.
The major players in this market are involved in strategic acquisitions and
product launches to expand their product portfolios. For instance, in May 2019,
Pfizer Inc. received US FDA approval for Vyndamax (tafamidis) and Vyndaqel
(tafamidis meglumine) for the treatment of cardiomyopathy.
However,
the side effects associated with the medication and presence of alternative
treatment methods are expected to hinder the growth of the global
cardiomyopathy medication market during the forecast period.
Regional
Analysis
The global
cardiomyopathy medication market has been segmented, by region, into the
Americas, Europe, Asia-Pacific, and the Middle East & Africa. The
cardiomyopathy medication market in the Americas has further been segmented
into North America and Latin America, with the North American market divided
into the US and Canada. The European cardiomyopathy medication market has been
divided into Western Europe and Eastern Europe. The market in Western Europe
has further been classified as Germany, France, the UK, Italy, Spain, and the
rest of Western Europe. The cardiomyopathy medication market in Asia-Pacific has
been segmented into Japan, China, India, South Korea, Australia, and the rest
of Asia-Pacific. The cardiomyopathy medication market in the Middle East &
Africa has been divided into the Middle East and Africa. The market in the
Americas is expected to dominate the global cardiomyopathy medication market
due to the increasing per capita healthcare expenditure and presence of a large
number of healthcare companies in the region. The market in Asia-Pacific is
projected to register the highest growth rate during the forecast period owing
to the increasing awareness of cardiac diseases and increasing government
initiatives for healthcare reforms.
Segmental
Analysis
The global
cardiomyopathy medication market has also been segmented based on type,
treatment, and end user.
Based on
type, the market has been segmented into dilated cardiomyopathy, hypertrophic
cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular
dysplasia, and unclassified cardiomyopathy. The dilated cardiomyopathy segment
is projected to hold the largest share of the market due to the presence of a
large patient population. The hypertrophic cardiomyopathy segment is expected
to be the fastest-growing wing to the increasing prevalence of hypertrophic
cardiomyopathy across the globe.
By
treatment, the global cardiomyopathy medication market has been categorized as
anticoagulants, antiarrhythmics, antihypertensives, cardiac glycosides, and
diuretics. The anti-hypertensives segment has been further divided into ACE
inhibitors, angiotensin II receptor blockers, beta-blockers, and calcium
channel blockers. The anti-hypertensives segment is expected to be the largest
due to the increasing demand for and high prescription rate of these medicines
for heart disease patients. Antiarrhythmics is anticipated to be the
fastest-growing segment due to the increasing preference for antiarrhythmics
drug in emergency situations to prevent heart attacks and strokes.
The end
user segments of the market are homecare, hospitals and clinics, and others.
The hospitals and clinics segment is expected to dominate the market during the
review period. The growth of the segment can be attributed to the high number
of patients visiting such institutions for diagnosis and treatment. Homecare is
projected to be the fastest-growing segment.
Key
Players
Some of the
key players in the global cardiomyopathy medication market are Pfizer Inc.
(US), PhaseBio Pharmaceuticals, Inc. (US), Array Biopharma, Inc. (US),
AstraZeneca (UK), Sanofi-Aventis US LLC (US), F. Hoffmann-La Roche Ltd (UK),
Merck & Co., Inc. (US), Capricor Therapeutics (US), MyoKardia (US), Janssen
Products, LP (US), Ionis Pharmaceuticals, Inc. (US), Medtronic (Ireland),
Becton And Dickson & Co. (US), Biomerieux (UK), and Teva Pharmaceutical
Industries Ltd (Israel).
Browse
Full Report Details @ https://www.marketresearchfuture.com/reports/cardiomyopathy-medication-market-8256
About
Market Research Future:
At Market
Research Future (MRFR), we enable our customers to unravel the complexity of
various industries through our Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), & Consulting Services. MRFR team have supreme
objective to provide the optimum quality market research and intelligence
services to our clients.
Have a Look at
Related Reports:
Cardiac Imaging Software Market
Contact
us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson
Street, 5Th Floor,
New York,
New York 10013
United
States of America
+1 628 258
0071
Email:
sales@marketresearchfuture.com
Comments
Post a Comment